Literature DB >> 30527342

Proton therapy for prostate cancer: A review of the rationale, evidence, and current state.

Trevor J Royce1, Jason A Efstathiou2.   

Abstract

Men diagnosed with localized prostate cancer have many curative treatment options including several different radiotherapeutic approaches. Proton radiation is one such radiation treatment modality and, due to its unique physical properties, offers the appealing potential of reduced side effects without sacrificing cancer control. In this review, we examine the intriguing dosimetric rationale and theoretical benefit of proton radiation for prostate cancer and highlight the results of preclinical modeling studies. We then discuss the current state of the clinical evidence for proton efficacy and toxicity, derived from both large claim-based datasets and prospective patient-reported data. The result is that the data are mixed, and clinical equipoise persists in this area. We place these studies into context by summarizing the economics of proton therapy and the changing practice patterns of prostate proton irradiation. Finally, we await the results of a large prospective randomized clinical trial currently accruing and also a large prospective pragmatic comparative study which will provide more rigorous evidence regarding the clinical and comparative effectiveness of proton therapy for prostate cancer.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Prostate; Protons; Radiation

Mesh:

Year:  2018        PMID: 30527342     DOI: 10.1016/j.urolonc.2018.11.012

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  8 in total

1.  Are simple verbal instructions sufficient to ensure that bladder volume does not deteriorate prostate position reproducibility during spot scanning proton therapy?

Authors:  Kentaro Nishioka; Kento Gotoh; Takayuki Hashimoto; Takashige Abe; Takahiro Osawa; Ryuji Matsumoto; Isao Yokota; Norio Katoh; Rumiko Kinoshita; Koichi Yasuda; Toshiaki Yakabe; Takaaki Yoshimura; Seishin Takao; Nobuo Shinohara; Hidefumi Aoyama; Shinichi Shimizu; Hiroki Shirato
Journal:  BJR Open       Date:  2021-11-11

2.  Proton Therapy for Primary Renal Cell Carcinoma: The First Nationwide Retrospective Study in Japan.

Authors:  Nobuyoshi Fukumitsu; Hitoshi Ishikawa; Takeshi Arimura; Hitoshi Wada; Tomoaki Okimoto; Yoshitaka Sato; Hiromitsu Iwata; Shosei Shimizu; Hideyuki Sakurai
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

3.  Assessment of Proton Beam Therapy Use Among Patients With Newly Diagnosed Cancer in the US, 2004-2018.

Authors:  Leticia M Nogueira; Ahmedin Jemal; K Robin Yabroff; Jason A Efstathiou
Journal:  JAMA Netw Open       Date:  2022-04-01

4.  DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.

Authors:  Rui-Xue Huang; Ping-Kun Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-05-01

5.  Simulation study using the spots deletion technique in spot scanning proton beam therapy for prostate cancers.

Authors:  Nobuyoshi Fukumitsu; Tomokatsu Hayakawa; Tomohiro Yamashita; Masayuki Mima; Yusuke Demizu; Takeshi Suzuki; Toshinori Soejima
Journal:  Mol Clin Oncol       Date:  2021-12-01

Review 6.  Proton Therapy for Prostate Cancer: Challenges and Opportunities.

Authors:  Darren M C Poon; Stephen Wu; Leon Ho; Kin Yin Cheung; Ben Yu
Journal:  Cancers (Basel)       Date:  2022-02-13       Impact factor: 6.639

7.  Dose distribution effects of spot-scanning proton beam therapy equipped with a multi-leaf collimator for pediatric brain tumors.

Authors:  Nobuyoshi Fukumitsu; Tomohiro Yamashita; Masayuki Mima; Yusuke Demizu; Takeshi Suzuki; Toshinori Soejima
Journal:  Oncol Lett       Date:  2021-07-01       Impact factor: 2.967

8.  DNA damage response in prostate cancer cells by proton microbeam irradiation.

Authors:  Xue Chen; Qi Yu; Xufei Wang; Ping Li; Qing Zhang; Shen Fu
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.